News

July 12, 2019 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today the appointment of Andrew Eisen, M.D., Ph.D. as

June 20, 2019 20:05 UTC ROCKVILLE, Md.--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today the promotion of Teri Heiland, Ph.D. to Chief Scientific Officer.

April 04, 2019 04:05 PM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. announced today that it will participate at the World Vaccine Congress Washington being held in Washington, D.C.

February 28, 2019 04:05 PM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. announced today that a poster will be presented by Immunomic scientists at the American Association for Cancer

Immunomic Therapeutics to Sponsor and Present at CHCI Health Summit February 26, 2019 04:05 PM Eastern Standard Time   ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. announced today that its’ Senior Vice

  February 06, 2019 05:00 PM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today that the company has granted Japanese animal

November 15, 2018 06:15 AM Eastern Standard Time SAN DIEGO--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI) announced today that the company will present and participate at the 2018 World Vaccine & Immunotherapy

November 07, 2018 06:00 AM Eastern Standard Time NEW ORLEANS--(BUSINESS WIRE)--On Friday, November 16, Immunomic Therapeutics Inc. (ITI) Scientist Amit Adhikara will present at the Society for NeuroOncology 2018 Annual

ITI's Michael Connolly, Manager of Process Development, presents a poster titled, "Functional evaluation of isoforms present in pDNA vaccines" at Aldevron's corporate offices located in Fargo, North Dakota A detailed abstract

Immunomic Therapeutics Senior Director of Corporate Development to Present at Precision Lung Cancer World R&D Summit Discussion of lysosomal targeting technology as applied in cancer immunotherapy October 26, 2018 07:30

Immunomic Therapeutics CEO to Present at NYC Oncology Investor Conference To Discuss UNITE Technology Application in Oncology October 23, 2018 07:00 AM Eastern Daylight Time   NEW YORK--(BUSINESS WIRE)--Immunomic Therapeutics,

 Immunomic Therapeutics, Inc. Founder and CEO Bill Hearl Joins Rich Bendis for BioTalk Click to hear the interview: Bill Hearl Q&A Dr. Bill Hearl is the Founder and Chief Executive Officer